Why it Matters
The Infant Safety Committee LLC marks its first federal lobbying effort by hiring Cornerstone Government Affairs Inc. This comes as Congress considers multiple infant safety bills while the Consumer Product Safety Commission faces elimination threats.
By the Numbers
- Three former Senate Appropriations Committee staff members
- Combined 50+ years of Capitol Hill experience
- Zero previous lobbying expenditures by the client
- Focus areas: Budget/Appropriations, Consumer Issues/Safety/Protection, and Health Issues
Key team members include Dianne Preece Nellor, an 18-year Capitol Hill veteran, and Erik Byrd Fatemi, who specializes in health care funding.
Broader Context
Recent infant formula crises have sparked congressional action on product safety. A House Oversight Committee hearing in January criticized FDA inspection failures that led to nationwide shortages. Meanwhile, the Trump administration faces resistance over attempts to eliminate the CPSC. Democratic senators including Amy Klobuchar (D-MN) and Maria Cantwell (D-WA) have called the moves illegal.
The Agenda
The committee targets budget/appropriations, consumer safety, and health issues without specifying particular legislation. However, several relevant bills are advancing through Congress, including H.R.4340 – Tyler’s Law, which would require hospitals to report child deaths from consumer products to the CPSC.
Competitive Landscape
- Safe Kids Worldwide lobbies comprehensively on child safety issues including CPSC reform.
- Infant formula companies like ByHeart Inc. and Mead Johnson & Co. LLC focus on manufacturing and FDA oversight.
- Dreamland Baby Co. monitors CPSC rulemaking specifically.
Between The Lines
Congress is actively considering infant safety legislation. The S.2371 – Safe Baby Formula Act of 2025 would establish contamination limits for heavy metals in formula. Sen. Katie Britt (R-AL) and Rep. Nancy Mace (R-SC) champion specific safety measures, showing bipartisan concern despite regulatory approach disagreements. Senate Appropriations Subcommittee hearings have raised concerns about FDA staff reductions undermining safety reviews.
The Bottom Line
The committee’s strategic timing and high-powered lobbying team position it to influence both funding and policy decisions. Success will depend on building bipartisan coalitions while navigating tensions between safety advocates and deregulation efforts.
—
All data used in this article came from Legis1. Request a demo to learn more!
Spot something wrong? Report an issue with this article